FDA Webview
X
about-us-banner

Articles

Home /Articles / FDA Federal Register Notices

Risk Communication Advisory Panel Established

06/05/2007

Federal Register Notice: FDA is establishing the Risk Communication Advisory Committee, which will provide advice to the commissio...

Watson Labs’ Address is Changed

06/05/2007

Federal Register Final rule: FDA is amending the animal drug regulations to reflect a change of sponsor address for Watson Laborat...

Nominations Sought for Risk Communication Committee

06/05/2007

Federal Register Notice: FDA is requesting nominations for members to serve on the Risk Communication Advisory Committee in the Of...

Review Period Set for Forest’s Namenda

06/05/2007

Federal Register Notice: FDA has determined the regulatory review period for Forest Pharmaceuticals’ Namenda 5,001 days for ...

Review Period Set for Zilmax

06/01/2007

Federal Register Notice: FDA has determined the regulatory review period for Intervet International BV’s Zilmax is 4,720 day...

Review Period Set for Phakic Lenses

06/01/2007

Federal Register Notice: FDA has determined the regulatory review period for Phakic Intraocular Lenses is 2,545 days for extending...

Guidance on Licensure of Pandemic Influenza Vaccines

06/01/2007

Federal Register Notice: FDA is making available Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic ...

Lantus Review Period Set

06/01/2007

Federal Register Notice: FDA has determined the regulatory review period for Sanofi aventis’ Lantus is 1,591 days for extend...

Seasonal Influenza Vaccine Guidance

06/01/2007

Federal Register Notice: FDA is making available: Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal...

Review Period Set for X-Stop Interspinous System

06/01/2007

Federal Register Notice: FDA has determined the regulatory review period for St. Francis Medical Technologies, Inc.’s X-Stop...